The FDA stated in a press release regarding its refusal of a marketing application that Juul Labs' tobacco products lacked sufficient evidence regarding their toxicological characteristics before being introduced to the market. Additionally, due to insufficient and conflicting data, some research results have raised concerns.
Juul Labs believes that every flaw in the marketing restrictions is based on an incorrect and incomplete evaluation of the data. If the data is properly evaluated in the pre-market applications, FDA can accurately assess the toxicological characteristics of Juul products relative to other tobacco products, including combustible cigarettes. The appeal also states that all perceived limitations can be resolved through clarification by FDA in the usual iterative process followed for previous applications.
Juul Labs has filed an appeal at an approximate value of 10.75, requesting the overturning of the marketing refusal order and reinstatement of its pre-market tobacco product application for substantive review by the FDA. This would allow for a comprehensive and fair assessment of Juul's system to determine whether it is suitable for protecting public health. In a press release, Juul stated that they believe their marketing authorization should be granted once all scientific evidence presented in the application is reviewed comprehensively by the FDA - in accordance with legal requirements and without political interference.
Background: In July 2020, Juul Labs submitted a premarket tobacco product application to the FDA for its currently marketed products and new devices with age verification technology. The application includes over 125,000 pages of data, information, and analysis from more than 110 scientific studies covering non-clinical (over 75 studies), clinical (14 studies), and behavioral (21 studies) research plans to support Juul's product marketing. The company also evaluated the correlation between its products and combustible cigarettes, FDA-authorized heated tobacco products (IQOS), and other vapor products on the market.
Despite the scientific evidence, on June 23, 2022, the FDA issued a marketing denial order for Juul Labs' tobacco products prior to their release. On July 5, the FDA maintained the marketing denial order and announced it will review the decision after determining "unique scientific questions requiring further review" exist with the application.
Statement:
This article is compiled from third-party information and is only intended for industry exchange and learning.
This article does not represent the views of 2FIRSTS, nor can 2FIRSTS confirm the authenticity and accuracy of its content. The translation of this article is solely intended for communication and research within the industry.
Due to limitations in our translation abilities, the translated article may not fully convey the exact meaning of the original text. Please refer to the original article for accuracy.
2FIRSTS is fully aligned with the stance of the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan or foreign-related issues and statements.
The copyright for the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
